Neglected Tropical Diseases (NTDs) not only cause health and life expectancy loss, but can also lead to economic consequences including reduced ability to work. This article describes a systematic literature review of the effect on the economic productivity of individuals affected by one of the five worldwide most prevalent NTDs: lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, trichuriasis, and hookworm infection) and trachoma. These diseases are eligible to preventive chemotherapy (PCT).
Eleven bibliographic databases were searched using different names of all NTDs and various keywords relating to productivity. Additional references were identified through reference lists from relevant papers. Of the 5316 unique publications found in the database searches, thirteen papers were identified for lymphatic filariasis, ten for onchocerciasis, eleven for schistosomiasis, six for soil-transmitted helminths and three for trachoma. Besides the scarcity in publications reporting the degree of productivity loss, this review revealed large variation in the estimated productivity loss related to these NTDs.
It is clear that productivity is affected by NTDs, although the actual impact depends on the type and severity of the NTD as well as on the context where the disease occurs. The largest impact on productivity loss of individuals affected by one of these diseases seems to be due to blindness from onchocerciasis and severe schistosomiasis manifestations; productivity loss due to trachoma-related blindness has never been studied directly. However, productivity loss at an individual level might differ from productivity loss at a population level because of differences in the prevalence of NTDs. Variation in estimated productivity loss between and within diseases is caused by differences in research methods and setting. Publications should provide enough information to enable readers to assess the quality and relevance of the study for their purposes.
Neglected Tropical Diseases (NTDs) not only have impact on health and life expectancy of mostly disadvantaged populations, but can also lead to economic consequences, including reduced ability to work. Investments in health improvement of the populations affected by NTDs would also help to increase economic growth of the affected regions, since healthier populations are more economically productive. We performed a systematic literature review to better understand how much NTDs affect people’s economic welfare. Here we present the results for the NTDs that are controlled with preventive chemotherapy (PCT): lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, trichuriasis, and hookworm infection) and trachoma. Our findings show that PCT NTDs clearly affect productivity, although the actual impact depends on the type and severity of the NTD as well as on the context where the disease occurs. Variation in estimated productivity loss is also caused by differences in research methods. Publications should provide enough information to enable readers to assess the quality and relevance of the study for their purposes.
Citation: Lenk EJ, Redekop WK, Luyendijk M, Rijnsburger AJ, Severens JL (2016) Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review. PLoS Negl Trop Dis 10(2): e0004397. https://doi.org/10.1371/journal.pntd.0004397
Editor: Darren J. Gray, Australian National University, AUSTRALIA
Received: April 28, 2015; Accepted: December 29, 2015; Published: February 18, 2016
Copyright: © 2016 Lenk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This study was funded by a grant (OPP1086560) from the Bill & Melinda Gates foundation. http://www.gatesfoundation.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Most of the people affected by Neglected Tropical Diseases (NTDs) are impoverished and marginalized populations, with low visibility and little political voice. They are not considered a priority market for pharmaceutical manufacturers or a health risk for the wealthier parts of the world. [1–3] Nevertheless, NTDs have an important impact on child development, school attendance, learning, nutritional status, pregnancy outcomes, and worker productivity, especially in poor rural settings, where physical labor is the major subsistence mode. As any other disease, they can lead to productivity loss in many ways, including reduced productivity at work (presenteeism), absence from work (absenteeism) or even job loss, depending on the type, severity and duration of the disease. [2–12]
Many publications in the literature describe the epidemiological and physical aspects of NTDs. In contrast, the impact of NTDs on paid and unpaid work and the productivity of individual men and women has been less frequently studied. Most of the data about the economic burden of NTDs come from small studies in restricted geographical areas.
The costs of treatment, mainly long-term ones, can inflict further economic difficulties in populations already struggling to live with less than US$ 1 a day. Besides the obvious advantages of decreasing the healthcare costs due to lack of care or delayed care, investments in health improvement would also help to increase economic growth of the affected regions since healthier populations are more economically productive. [14–16]
As part of the movement to increase the attention given to NTDs, a coalition of many stakeholders gathered in January 2012 to discuss the importance of reaching the 2020 WHO goals for this group of diseases. As a result, the London Declaration was signed by many partners, committed to eradicate Guinea worm disease, eliminate three NTDs (lymphatic filariasis, leprosy, African sleeping sickness (human African trypanosomiasis) and blinding trachoma) and control the others (schistosomiasis, soil-transmitted helminths, Chagas disease, visceral leishmaniasis and river blindness (onchocerciasis)). [17,18]
A better understanding of the effect that NTD have on people’s economic livelihood would be an additional argument in favor of controlling or eliminating them. With this in mind, we performed a systematic literature review to identify and examine publications describing the impact of the London Declaration NTDs. Here we present the results for the five most prevalent ones, which are the ones eligible for preventive chemotherapy (PCT diseases): lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, trichuriasis, and hookworm infection) and trachoma on productivity loss in adults. [7,19,20]
We performed a comprehensive search of the literature relating to the economic impact of all of the NTDs included in the London Declaration. Databases searched included Embase, Medline (OvidSp), Web of Science, Scopus, CINAHL, PubMed publisher, Cochrane, Popline, Lilacs, Scielo and Google Scholar. The search terms aimed at identifying articles about direct costs of treatment (such as consultation fees, medication, transport, food, assistance, accommodation), as well as indirect labor costs arising from decreased working hours and reduced economic activity attributable to morbidity. The search strategy included the names of the ten London Declaration NTDs (since many articles mention more than one) and words such as: ‘economic', 'financ', 'cost', 'productivity', 'absenteeism', 'employment', and 'cost'. A detailed list of the keywords used for each database is found in Supporting Information (S1 File). The search only considered title and abstracts, did not use any time restriction, and was restricted to the English language. The main database search was conducted in November 2013. There is no review protocol registered. This search included not only productivity loss, but also direct costs for all 10 London Declaration NTDs for a larger project. The results found in this article are limited to the results of the literature search regarding productivity loss from PCT NTDs.
The databases were merged according to the order shown in Table 1. Duplicates were removed automatically using Endnote and the remaining articles were then compared manually using author, year, title, journal, volume and pages to identify any additional duplicates.  After duplicates were excluded, we selected the articles that were related to each particular disease and screened the abstract and title of all papers to identify the ones that might provide information on productivity or indirect costs. The full-text versions of all remaining articles were then examined. Articles that did not contain any information on productivity, or only qualitative information on productivity loss (without any quantitative measures) were excluded, as well as articles that investigated productivity loss in children. Since the number of relevant publications was expected to be small, no restrictions were made regarding populations (participants), interventions, comparisons, outcomes, study design, or length of follow-up. Articles that could not be retrieved through their respective journals, contacting libraries, or after contacting the authors were classified as ‘not available’ and excluded from the selection. Any additional relevant articles identified when reading the full-text articles or checking their reference lists (i.e., the ‘snowball’ search strategy) were screened using abstract and title and then examined in more detail if they were considered potentially relevant.
In addition to searches using databases relating to the ‘white’ literature, we also searched the grey literature by screening websites of relevant organizations (i.e. World Health Organization, the Centre for Neglected Tropical Diseases, the Carter Center) (see S2 File). The list of selected articles for each disease was sent to disease experts identified in the literature and from institutions researching/combating NTDs, to check if the selection was comprehensive.
Data were extracted from selected articles independently, using a standardized Excel sheet, for the variables: author, year, study design, population, sample size, follow-up period, country, region, disease sequela, definition of productivity loss and results. Disease sequelae are disease manifestations, which for this review were defined by the Global Burden of Disease 2010 study (see S1 Table).  No summary measure was chosen beforehand. Instead, the results were presented separately per disease and study and described as they were reported in the articles; results were not statistically combined.
If the productivity loss was not already described in percentages of annual productivity in the articles, we calculated it whenever the unit of measurement made it possible, for the sake of comparability between studies and diseases. A working year was assumed to consist of 300 working days. 
Since the outcome of interest was productivity loss, various study designs were expected. The studies were therefore critically appraised regarding general criteria of selection, performance, attrition, detection, and reporting biases, as specified in the Cochrane Handbook for Systematic Reviews of Interventions. [24,25] Therefore, each article was given a rating regarding the risk of bias (possible options: low, high or unclear) for each criterion as well as a summary rating. [24,25] We added an extra criterion about the degree of relevance that the study outcomes defined as productivity loss had in terms of quantifying productivity loss in adults due to an NTD. This ‘relevance’ criterion was also rated as low or high. This review was conducted according to the PRISMA checklist for systematic reviews.
Results of the database searches
Table 1 provides an overview of the databases searched and the number of articles identified through each of them. In total, 11,449 articles regarding all 10 NTDs were identified using the database searches. Of these, 5,316 articles remained after duplicates were removed. There was no duplication across the various NTDs.
From the main database, 281 peer reviewed papers were related to lymphatic filariasis (LF). The grey literature search and snowballing method added 24 more articles, resulting in 305 articles being screened by title and abstract. Of the 72 full-text publications that were examined, 13 quantitatively described productivity loss related to LF (S1 Fig).
Lymphedema and hydrocele due to lymphatic filariasis are the two sequelae considered by the GBD study for this disease. Acute dermatolymphangioadenitis (ADLA) is part of these sequelae as acute inflammatory attacks suffered by most of the chronic patients, sometimes many times a year.
An overview of the studies that used a quantitative method to describe productivity loss from lymphatic filariasis can be seen in Table 2, together with the calculated percentages of productivity loss.
Productivity loss in LF patients can occur because of ADLA or the chronic sequelae of the disease (lymphedema and hydrocele). Our search identified six studies that examined only the acute attacks (ADLA), five articles that described the impact of chronic sequelae, and two that measured both.
The range in estimated productivity loss during ADLA attacks was 77–100% during the days of the attacks. The ranges in annual productivity loss reported in the literature were 10–26% for lymphedema and 15–19% for hydrocele (only the chronic sequelae). However, studies of productivity loss due to lymphedema and hydrocele rarely considered the different stages and varying severity of these symptoms. Most of the studies describing productivity loss due to LF measured it by comparing lost working hours or days amongst workers with LF with those seen amongst healthy workers.
Of the 5316 articles in the source database, only 167 articles were related to onchocerciasis. In addition, 52 articles were found through the ‘snowball’ search and grey literature sources, which meant that a total of 219 articles were screened on abstract and title. Of these, 57 articles remained for full-text examination; from which only 10 contained quantitative information on productivity losses related to onchocerciasis (S2 Fig).
The GBD sequelae (disease manifestations) considered for onchocerciasis were skin disease and vision loss.
Table 3 provides an overview of studies that have quantitatively examined productivity loss resulting from onchocerciasis. Only one study—by Thomson—reported productivity loss due to onchocerciasis in general, of 20%. The other papers focused on the effects of the specific sequelae of onchocerciasis on productivity.
Four studies examined productivity loss related to onchocerciasis skin disease (OSD) [27–30]. Two of these studies compared Ethiopian coffee plantation workers with OSD to uninfected workers at the same plantation: Workneh et al. concluded that workers with OSD had a one-year income that was 25% lower than that of healthy workers while Kim et al.  found 10–15% lower daily wages of individuals with OSD compared to those without. The study by Oladepo et al.  focused on the utilization of land and found that men with OSD had a significantly smaller (34%) amount of land than men without OSD. The study by the World Bank  found that individuals with onchocerciasis spent less time per day performing productive activities (farming and non-farming) and household activities than healthy individuals. However, these differences were not statistically significant.
Evans (1995) discussed the economic impact of blinding onchocerciasis , and found that visual acuity was strongly associated with occupational status. Approximately 80% of people that were blind due to onchocerciasis did not work, compared to 60% of the visually impaired (due to onchocerciasis) and 2% of the sighted.
Three studies (Thomson ; Wogu et al.  and Okeibunor et al. ) described in more general terms the socioeconomic consequences of onchocerciasis. For instance, Wogu et al.  reported that 13.5% of individuals with onchocerciasis-related itching experienced reduced concentration at work. In addition, 14% of the individuals with ocular lesion reported that they gave up their jobs because of visual impairment. Similarly, Okeibunor et al.  found that 76% of their subjects reporting increased productivity after (community based) treatment with ivermectin.
In addition to the observational studies of onchocerciasis-related productivity loss, we also identified several economic evaluations that considered productivity loss in their analyses. Two cost-benefit analyses, one by Benton and another by Kim, included productivity gains due to prevention of onchocerciasis blindness as part of the benefits of prevention. [34,35]. However, these gains were not actually observed in a patient population but based on the assumption that blind individuals are not productive at all. Kim et al.  assumed that each prevented case of blindness would result in 20 years of extra productivity.
From the main search database, 670 articles referred to schistosomiasis, including publications identified through ‘snowball’ searching and grey literature sources. Of these, 26 articles were retrieved for full-text examination and eleven of them contained quantitative information on productivity losses caused by schistosomiasis (S3 Fig).
Three different worms of the genus Schistosoma can cause schistosomiasis: Schistosoma haematobium, Schistosoma mansoni, and Schistosoma japonicum. Ten sequelae were included for schistosomiasis in the GBD study: mild diarrhea, mild anemia, moderate anemia, severe anemia, hepatomegaly, hematemesis, ascites, dysuria, bladder pathology, and hydronephrosis due to schistosomiasis.
Table 4 provides a list of the studies investigating productivity loss attributable to schistosomiasis and the calculated percentages of annual productivity loss.
The studies vary regarding schistosomiasis being caused by S. haematobium, S. mansoni or S. japonica and also regarding the sequela they focused on. Most of the studies we identified compared productivity loss between infected and uninfected workers in a company or municipality, whereas Blas et al. and Wright et al. calculated the costs of productivity loss based on assumptions and not on empirical data. [36,37] Productivity loss was also measured using different units: lost man-days/work days [38–41], reduced earnings/bonus/incentives [42–44], cane cut , and lost working hours .
In total, 538 articles in the source database were related to soil-transmitted helminths (STH)(ascariasis, trichuriasis and hookworm disease). The snowballing method and the gray literature search yielded an additional 48 articles, which meant that 586 articles were screened by title and abstract. Of the 72 publications that were fully read, only 6 had information related to productivity loss and STH (S4 Fig).
The GBD study lists the following sequelae related to each of the STH diseases: infestation, severe wasting, and mild abdominopelvic problems, as well as anemia only for hookworm disease.
Table 5 shows the list of studies, the summary of their findings regarding productivity loss as a consequence of STH, and the yearly percentages that were calculated wherever needed.
Productivity loss from STH infection was generally measured by comparing infected to uninfected controls. Wolgemuth et al. observed that road construction workers with infection showed 6% less productivity (measured using volume of earth moved) than other workers.  Tanner et al. compared the agricultural and hunting or fishing yields reported in a 24-hour period among an indigenous Amazonian group of hunter–horticulturalists. There was a negative association of hookworm infection for both women and men, with hookworm-infected people reporting an average quantity of crops that was 35.29% less than uninfected people (no statistical significance). 
Productivity loss associated with anemia was mostly measured in women with three studies, by Casey et al., Gilgen et al., and Selvaratnam et al. [48–50] One study by Basta et al. investigated men  and one by Wolgemuth et al. investigated both women and men. Two studies compared anemic versus non-anemic workers—Basta, and Gilgen [51,52], while three studies examined the productivity of the same individual twice, once while anemic and infected by STH and once after an intervention to increase the hemoglobin level—Casey, Selvaratnam, Wolgemuth [46,48,50], with or without deworming. The only randomized controlled trial was performed by Gilgen et al., assessing iron supplementation with and without deworming, with a significant negative association between hookworm infection and ferritin levels. Furthermore, anemic workers had a poorer performance regarding kilograms of leaves plucked and wages earned by day, as well as more sick and absent days compared to non-anemic workers.  There were two studies describing a positive linear association between hemoglobin and productivity. Selvaratnam et al found that an increase in 1g/dL in hemoglobin corresponded with an increase in 26% in a worker’s productivity.  Wolgemuth et al. described a linear increase in productivity ranging from 3.5% to 5.6% (depending on the formula used in the study) for each 1g/L in hemoglobin gain.
In total, 538 articles from the initial search were related to trachoma and 11 articles were found through the ‘snowball’ search and grey literature sources, which led to a sum of 549 articles that were screened on title and abstract. Of these, 22 articles remained for full-text examination (S5 Fig).
The only sequela considered by the GBD study for trachoma was vision loss (from low vision to blindness).
A summary of the main features of the studies that investigated productivity loss due to trachoma quantitatively is shown in Table 6.
Of the studies we identified, none of them directly observed the extent of productivity loss caused by trachoma in a population. The three studies that examined this topic made assumptions about productivity loss in order to calculate the costs. [53–55] These studies assumed a productivity loss of either 60% or 100% for blindness and 24.5% for visual impairment and these percentages were based on the disability weights that existed at the time of the studies.
Risk of bias
Sixty percent of the selected articles had a high overall risk of bias (26 articles of 42), mostly due to detection bias (24 of 42 articles), selection bias (21 articles of 42), and attrition bias (10 of 42 articles). Twenty-two articles were rated as relevant, and of these studies, two-thirds (14/21) had a high overall risk of bias, 2 had a low overall risk of bias and 6 had an unclear overall risk. Only 6 articles had a low overall risk of bias, of which only 2 were relevant, and 9 had an unclear summary rating, of which 6 were relevant (as described before). No particular trend was observed, regarding over- or underestimation of results due to bias. For the complete risk of bias assessment table, please refer to S3 Table.
Neglected tropical diseases can have a profound effect on the health and economic livelihood of the individuals suffering from them as well as that of their families. We examined what has been published in the literature regarding the loss in productivity seen amongst patients with the NTDs that are eligible for preventive chemotherapy: lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (ascariasis, trichuriasis, and hookworm infection) and trachoma. In general, our systematic literature review revealed that few studies have actually examined the degree of productivity loss related to these NTDs, which to some extent might have been influenced by the focus on literature written in English. Table 7 shows a summary of the flowcharts for all PCT NTDs, which shows the relatively small numbers of articles containing quantitative information on productivity loss related to PCT NTDs compared to the number of the publications screened by title and abstract.
We also found large variation in the definition of productivity loss as well as the estimated productivity loss as reflected in percentage productivity loss over a one-year period. This is not surprising given the diversity in the methods chosen to quantify absolute and relative productivity loss, the many symptoms that these NTDs can cause, and the many different contexts of the different countries and regions where these diseases are endemic.
Many of these studies were performed many years ago and involved very specific populations in specific countries. However, besides biological reasons, there are methodological reasons for this variation. One explanation is simply random variation, where the results of two studies with the very same study design simply differ due to chance. A more important issue relates to the fact that studies varied in their approach when examining productivity loss. First of all, studies varied in their selection of the study population. Many studies focused on workers on large plantations, while others observed road workers, and the different studies were performed in different settings and countries, which might differ in important ways from other professions and other populations suffering from the same NTD elsewhere. The generalizability of the results from one study to another population must therefore be carefully considered.
The second type of variation in study design relates to the choice of comparison group. Most studies chose workers who did not have the NTD as the comparison group (only one, Gyapong 1996, compared patients with lymphatic filariasis with patients with other febrile diseases). The sometimes tacit assumption made with this comparison is that any difference in productivity can be attributed to the NTD and its symptoms. However, the validity of this comparison can be questioned, certainly if no correction is made for background characteristics such as age, sex, job experience, diet, height, and BMI (body mass index), which can affect productivity. Fortunately, some but not all studies included these factors when analyzing and reporting their results. Other studies did not compare two different populations but used a before-after study design to see how much productivity improved after treatment. This approach focuses directly on the productivity gain that can be achieved using available treatments.
The third type of variation relates to the actual measure of productivity. Many studies used the number of hours or days to quantify productivity. In contrast, some studies used other, arguably more accurate, methods which involved examining the volumes that were actually collected or processed per day (i.e. how many kilograms of tea were plucked per day).  Some studies even used multiple outcomes to study productivity loss. Ultimately, one could argue that the choice of outcome measure should be based on what a decision-maker considers important. For example, an employer might be particularly interested in volume outcomes since workers with an NTD who never miss a day at work may nevertheless be less productive than other workers. Another point worth considering when measuring productivity loss is that the adjustment of worker behavior and the associations between nutrition, body composition, and work productivity may be more complex. Workers might adapt work pace or intensity, allowing them to minimize the effects of poor health on work productivity. 
The fourth type of variation relates to the length of time that productivity loss is measured. Most studies used a fixed length of time (e.g., year) when measuring productivity, also to account for seasonality, which could also influence productivity along the year. In some instances, however, the length of time was disease-based (e.g., length of an episode). This approach may reveal that productivity loss is very high (>50%) if the symptoms are extreme, but the impact of disease on productivity over a longer period (e.g., one year) may be small if these episodes last just a few days and only occur a couple of times per year.
Other limitations of the studies are worth mentioning. Firstly, many studies did not check for other concomitant NTDs prevalent in the same region. One possible reason for this could be the assumption that the control group has the same risk to be affected by the non-investigated disease as the case group. Secondly, measurement of productivity loss in working populations may lead to an underestimation of impact due to the ‘healthy worker effect’, since people who had to stop working because of the disease are excluded from the study . Thirdly. most of the studies that diagnosed NTDs using stool examination took only one sample, which resulted in a high probability of false negatives and a possible underestimation of productivity loss due to the NTD. [56–58] Lastly, correction of hemoglobin levels for altitude or for smoking status of the patients was not mentioned by any of the anemia studies, which could also lead to an underestimation of the productivity loss. 
Based on the literature, the NTDs with the greatest impact on an individual’s productivity loss are onchocerciasis and trachoma, because both of them can lead to blindness. The studies of actual patients revealed an increased likelihood of stopping with work or a substantial decrease in productivity. However, other studies simply assumed that productivity loss would be high.
It is important to distinguish between productivity loss at an individual level from productivity loss at a population level. For example, while the individual productivity loss from an NTD like STH may be much less than loss from another NTD like onchocerciasis, the overall impact of STH at a population level may be greater than that of onchocerciasis as a result of its higher prevalence. Therefore, what we consider important depends on the perspective we are taking (either that of the individual or that of the population).
The extent to which productivity is affected by diseases–in this case NTDs–can also help to understand the economic burden of diseases for affected individuals, countries, regions, and even globally. If we take the example of STH in India, around 50 million cases of hookworm (in adults older than 15 years) would be expected in 2020 if the epidemiological situation in 1990 had continued unabated. If we assume an annual income of US$1333 (which equals the annual income of an individual in the lowest GDP quintile in India in 2005) and an average productivity loss due to hookworm anemia of 6%, we could estimate an economic burden from productivity loss of roughly US$ 4 billion just in that one year. Obviously, the impact is much more pronounced when other years or countries are considered. These estimates can help to estimate the impact on productivity of achieving the targets described in the 2012 London Declaration. 
Some recommendations regarding future studies of productivity loss can also be made. The assessment of productivity loss secondary to NTDs should be further researched to enable a better understanding of the economic burden it generates. Additional research is needed to develop standard methods to describe absolute and relative productivity loss. However, this will not be an easy task, given the diverse symptoms caused by these diseases and the variety of countries and cultures where these diseases are endemic; with some NTDs such as lymphatic filariasis, a distinction between treated and untreated patients will have to be made as well. As described above, there are some factors that should be considered when designing future studies: the choice of the comparison group (preferably a comparable assuredly non-infected group), the outcome measure assessing productivity (preferably quantitative), the length of the assessment (not only during acute attacks, accounting for seasonal variation), and confounders of the disease effect on the productivity/work performance (for instance nutrition, BMI, type of work/profession). These elements should be transparently described and their (missing) values discussed, to determine how much they might have influenced the results. In particular, researchers should provide sufficiently detailed information to enable readers to assess the quality and relevance of the study.
Various studies have examined productivity loss in patient populations having one of the five most prevalent NTDs. While is clear that these diseases reduce productivity, the actual impact depends on the type, severity and duration of the NTD as well as on the setting. Variation in estimated productivity loss between and within diseases is caused by differences in the different definition of productivity loss, research methods and setting. It is therefore important to examine the literature carefully to understand what was actually observed in order to draw conclusions about the generalizability of the studies. Since productivity loss is an important aspect of the burden of diseases, further research on better estimates of the magnitude of the productivity loss caused by NTDs would enable a more complete picture of their economic burden to individuals, countries, and globally, adding an additional persuasive argument in favor of their control.
This review already contributes to a better perception of the magnitude of the effect of an NTD on people’s working and economic situation, and can already offer additional arguments in favor of controlling and eliminating them. However, there is still much room for further research in this field to improve the understanding on NTDs’ effects on individuals’ productivity loss.
S1 Table. List of disease sequelae according to the 2010 GBD study.
S2 Table. Risk of bias assessment table.
To which extent it measured productivity loss caused by NTD quantitatively. CBA—Cost-benefit analysis. CEA–Cost-effectiveness analysis. OBS–Observational study. RCT–Randomized controlled trial.
S1 Fig. Flowchart describing the literature search for lymphatic filariasis.
S2 Fig. Flowchart describing the literature search for onchocerciasis.
S3 Fig. Flowchart describing the literature search for schistosomiasis.
S4 Fig. Flowchart describing the literature search for soil-transmitted helminths.
We would like to express our gratitude to Tanja Houweling, Margarete Kulik, who contributed to the development of this work with valuable comments and insights.
We are especially grateful to Wichor Bramer, whose work as a biomedical information specialist was crucial in designing the most comprehensive possible syntaxes for our literature reviews.
Conceived and designed the experiments: EJL WKR ML AJR. Performed the experiments: EJL WKR ML AJR. Analyzed the data: EJL WKR ML AJR. Wrote the paper: EJL WKR ML JLS.
- 1. Hotez PJ. NTDs V.2.0: "Blue-Marble Health"—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape. Plos Neglected Tropical Diseases 2013 November 21;7(11):e2570. pmid:24278496
- 2. Samuels F, Pose RR. Why neglected tropical diseases matter in reducing poverty. Development Progress 2013;Working paper 03.
- 3. Hotez P, Ottesen E, Fenwick A, Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol 2006;582:23–33. pmid:16802616
- 4. The Cochrane Collaboration. Neglected Tropical Diseases. 2010; Available at: http://www.thecochranelibrary.com/details/collection/805883/Neglected-tropical-diseases.html. Accessed Apr/08, 2014.
- 5. World Health Organization. Neglected Tropical Diseases. Available at: http://www.who.int/neglected_diseases/diseases/en/. Accessed Apr/08, 2014.
- 6. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet 2010 Jan 16;375:239–247. pmid:20109925
- 7. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. N Engl J Med 2007 Sep 6;357(10):1018–1027. pmid:17804846
- 8. CDC—Centers For Disease Control and Prevention. Neglected Tropical Diseases. 2011; Available at: http://www.cdc.gov/globalhealth/ntd/diseases/index.html. Accessed Apr/08, 2014.
- 9. Hotez P. Stigma: The Stealth Weapon of the NTD. PloS Neglected Tropical Diseases 2008 April 30;2(4):e230. pmid:18446206
- 10. Hotez P. One World Health: Neglected Tropical Diseases in a Flat World. Plos Neglected Tropical Diseases 2009 April 28;3(4):e405. pmid:19399165
- 11. King CH, Bertino AM. Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Negl Trop Dis 2008;2:e209. pmid:18365036
- 12. World Health Organization. WHO guide to identifying the economic consequences of disease and injury. 2009:132pg.
- 13. Savioli L. The burden and impact of NTDS: An overview. Trop Med Int Health 2011;16:18–19.
- 14. World Health Organization, Asian Development Bank. Addressing diseases of poverty: an initiative to reduce the unacceptable burden of neglected tropical diseases in the Asia Pacific region. 2014.
- 15. Martin G, Grant A, D'Agostino M. Global health funding and economic development. Globalization Health 2012;8.
- 16. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases Review. Lancet 2009 May 2;373:1570–1575. pmid:19410718
- 17. Uniting to Combat Neglected Tropical Diseases. Uniting to Combat NTDs & The London Declaration. Available at: http://unitingtocombatntds.org/uniting-combat-ntds-london-declaration. Accessed Apr/07, 2014.
- 18. World Health Organization. London Declaration. 2012; Available at: http://www.who.int/neglected_diseases/London_Declaration_NTDs.pdf. Accessed Apr/08, 2014.
- 19. Imperial College London. 7 most prevalent Neglected Tropical Diseases. Available at: http://www3.imperial.ac.uk/schisto/whatwedo/7ntds. Accessed March/11, 2015.
- 20. The Global Network for Neglected Tropical Diseases. The 7 Most Common NTDs. Available at: http://www.globalnetwork.org/neglected-tropical-diseases/fact-sheets. Accessed March/11, 2015.
- 21. Bramer W. Manual on Deduplicating in EndNote–the Bramer method. Research 2015 November, 24:2 pgs.
- 22. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. The Lancet; 380(9859):2063–2066.
- 23. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The Economic Benefits Resulting from the First 8 Years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). Plos Neglected Tropical Diseases 2010 Jun;4.
- 24. Higgins JPT, Green S(. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011; Available at: www.cochrane-handbook.org. Accessed February/20, 2015.
- 25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007 Oct 20;335(7624):806–808. pmid:17947786
- 26. Thomson IG. Onchocerciasis in an oil palm estate. Trans R Soc Trop Med Hyg 1971;65:484–489. pmid:5315409
- 27. Oladepo O, Brieger WR, Otusanya S, Kale OO, Offiong S, Titiloye M. Farm land size and onchocerciasis status of peasant farmers in south- western Nigeria. Trop Med Int Health 1997;2:334–340. pmid:9171841
- 28. Kim A, Tandon A, Hailu A. Health and Labor Productivity: The Economic Impact of Onchocercial Skin Disease. 1997.
- 29. Workneh W, Fletcher M, Olwit G. Onchocerciasis in field workers at Baya Farm, Teppi Coffee Plantation Project, southwestern Ethiopia: Prevalence and impact on productivity. Acta Trop 1993;54:89–98. pmid:7902651
- 30. The World Bank. Economic impact of onchocercal skin disease (OSD): Report of a multi-country study. 1997 July.
- 31. Evans TG. Socioeconomic consequences of blinding onchocerciasis in west Africa. Bull World Health Organ 1995;73:495–506. pmid:7554022
- 32. Wogu M.D. OCE . Prevalence and socio-economic effects of onchocerciasis in Okpuje, Owan West Local Government Area, Edo State, Nigeria. International Journal of Biomedical and Health Sciences 2008 September 30;4(3):113–119.
- 33. Okeibunor JC, Amuyunzu-Nyamongo M, Onyeneho NG, Tchounkeu YFL, Manianga C, Kabali AT, et al. Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa. Trop Med Int Health 2011;16:608–621. pmid:21395925
- 34. Benton B. Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann Trop Med Parasitol 1998 Apr;92 Suppl 1:S33–9. pmid:9861265
- 35. Kim A. BB. Cost-Benefit Analysis of the Onchocerciasis Control Program (OCP). 1995 May:29 pg-ISBN: 978-0-8213-3235-1.
- 36. Blas BL, Lipayon IL, Tormis LC, Portillo LA, Hayashi M, Matsuda H. An attempt to study the economic loss arising from Schistosoma japonicum infection and the benefits derived from treatment. Southeast Asian J Trop Med Public Health 2006;37:26–32. pmid:16771209
- 37. Wright WH. A consideration of economic impact of schistosomiasis. Bull World Health Organ 1972;47:559–565. pmid:4540674
- 38. Audibert M, Etard J. Impact of schistosomiasis on rice output and farm inputs in Mali. Journal of African Economies 1998 2013/11/15;7:185–207.
- 39. Leshem E, Maor Y, Meltzer E, Assous M, Schwartz E. Acute schistosomiasis outbreak: Clinical features and economic impact. Clin Infect Dis 2008;47:1499–1506. pmid:18990059
- 40. Wu X, Wang T, Lu D, Hu H, Gao Z, Zhu C, et al. Studies of impact on physical fitness and working capacity of patients with advanced Schistosomiasis japonica in Susong County, Anhui Province. Acta Trop 2002 5;82(2):247–252. pmid:12020898
- 41. Umeh JC, Amali O, Umeh EU. The socio-economic effects of tropical diseases in Nigeria. Econ Hum Biol 2004;2:245–263. pmid:15464005
- 42. Barbosa FS, Costa PD. Incapacitating effects of schistosomiasis mansoni on the productivity of sugar-cane cutters in northeastern Brazil. Am J Epidemiol 1981 Jul;114:102–111. pmid:7246517
- 43. Kamel MI, Moustafa YA, Foda N, Khashab S, Moemen M, Naga AE. Impact of schistosomiasis on quality of life and productivity of workers. East Mediterr Health J 2002;8:354–362. pmid:15339125
- 44. Fenwick A. The costs and a cost-benefit analysis of an S. mansoni control programme on an irrigated sugar estate in northern Tanzania. Bull World Health Organ 1972;47:573–578. pmid:4540676
- 45. Fenwick A. Effect of a control programme on transmission of Schistosoma mansoni on an irrigated estate in Tanzania. Bull World Health Organ 1972;47:325–330. pmid:4539820
- 46. Wolgemuth JC, Latham MC, Hall A, Chesher A, Crompton DW. Worker productivity and the nutritional status of Kenyan road construction laborers. Am J Clin Nutr 1982 Jul;36(1):68–78. pmid:7091036
- 47. Tanner S, Rosinger A, Leonard WR, Reyes-Garcia V. Health and adult productivity: The relation between adult nutrition, helminths, and agricultural, hunting, and fishing yields in the Bolivian Amazon. Am J Human Biol 2013;25:123–130.
- 48. Casey GJ, Sartori D, Horton SE, Phuc TQ, Phu LB, Thach DT, et al. Weekly iron-folic acid supplementation with regular deworming is cost-effective in preventing anaemia in women of reproductive age in Vietnam. Plos One 2011;6.
- 49. Gilgen D, Mascie‐Taylor C, Rosetta L. Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh. Tropical medicine & international health 2001;6(6):449–457.
- 50. Selvaratnam RR, de Silva LD, Pathmeswaran A, de Silva NR. Nutritional status and productivity of Sri Lankan tea pluckers. Ceylon Med J 2003;48:114–118. pmid:15125401
- 51. Basta SS, Soekirman , Karyadi D, Scrimshaw NS. Iron deficiency anemia and the productivity of adult males in Indonesia. Am J Clin Nutr 1979;32:916–925. pmid:107787
- 52. Gilgen D, Mascie‐Taylor C, Rosetta L. Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh. Tropical medicine & international health 2001;6(6):449–457.
- 53. Frick KD, Basilion EV, Hanson CL, Colchero AM, Luo B, Brown MM. Estimating the burden and economic impact of trachomatous visual loss. Evid -Based Eye Care 2003;4:210–211.
- 54. Frick KD, Hanson CL, Jacobson GA. Global burden of trachoma and economics of the disease. Am J Trop Med Hyg 2003 Nov;69(5 Suppl):1–10. pmid:14692674
- 55. Frick KD, Lietman TM, Holm SO, Jha HC, Chaudhary JSP, Bhatta RC. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Organ 2001 2013/11/15;79:201–207. pmid:11285663
- 56. Nikolay B, Brooker SJ, Pullan RL. Sensitivity of diagnostic tests for human soil-transmitted helminth infections: a meta-analysis in the absence of a true gold standard. Int J Parasitol 2014 10/1;44(11):765–774. pmid:24992655
- 57. Glinz D, Silué KD, Knopp S, Lohourignon LK, Yao KP, Steinmann P, et al. Comparing diagnostic accuracy of Kato-Katz, Koga agar plate, ether-concentration, and FLOTAC for Schistosoma mansoni and soil-transmitted helminths. PLoS Negl Trop Dis 2010 Jul 20;4(7):e754. pmid:20651931
- 58. Knopp S, Speich B, Hattendorf J, Rinaldi L, Mohammed KA, Khamis S, et al. Diagnostic accuracy of Kato-Katz and FLOTAC for assessing anthelminthic drug efficacy. PLoS Negl Trop Dis 2011 Apr 5;5(4):e1036. pmid:21532740
- 59. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Available at: http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed March/19, 2015.